Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar wsantan (< 20) Submitted: 3/19/2011 3:30:41 PM : Outperform Start Price: $4.43 EXEL Score: -2.60

This stock has a lot of momentum with the great performance of its prostate cancer drug, it will continue to gain speed with each new successful trial.

Featured Broker Partners


Advertisement